Table II.

Current treatments used or tested in clinical trials

Treatments with antiviral potential:

Remdesivir: at best mild efficacy

Possible renal adverse events

Not to be initiated or to be stopped if ALAT≥5 N

Low risk of drug interactions (check and update if co-prescription)

Convalescent plasma: unproven efficacy

No serious adverse events expected

Monitor according to usual transfusion procedures

Casirivimab and imdevimab monoclonal antibody (Mab) cocktail (REGN-COV2): unproven efficacy

No specific interaction expected

Possible hypersensitivity reaction or infusion-related reaction

Monitor as for any mAb infusion

Treatments acting on the consequences of inflammation:

Corticosteroids: proven efficacy of dexamethasone in immunocompetent adults with a severe form of COVID-19 [29]

Unproven efficacy in immunocompromised patients

Baricitinib: potential efficacy in combination with remdesivir

Potential interaction with methotrexate in theory but no evidence in clinical practice

Tocilizumab: controversial efficacy

No obvious interactions with chemotherapy

Anakinra: unproven efficacy

No obvious interactions with chemotherapy

Eculizumab: unproven efficacy

Randomized protocols in progress in adults